Hepatic FTO is dispensable for the regulation of metabolism but counteracts HCC development in vivo

Melanie J. Mittenbühler\textsuperscript{1,2}, Katarzyna Saedler\textsuperscript{1,2}, Hendrik Nolte\textsuperscript{3}, Lara Kern\textsuperscript{1,2}, Jun Zhou\textsuperscript{4}, Shu-Bing Qian\textsuperscript{4}, Lydia Meder\textsuperscript{5,6}, Roland T. Ullrich\textsuperscript{5,6,7,8}, Jens C. Brüning\textsuperscript{1,2,6,*}, F. Thomas Wunderlich\textsuperscript{1,2,6,*}

ABSTRACT

Objective: Single-nucleotide polymorphisms in the FTO gene encoding an m\textsuperscript{6}Am and an m\textsuperscript{6}A demethylase are associated with obesity. Moreover, recent studies have linked a dysregulation of m\textsuperscript{6}A modifications and its machinery, including FTO, to the development of several forms of cancers. However, the functional role of hepatic FTO in metabolism and the development and progression of hepatocellular carcinoma (HCC), a prototypic obesity-associated cancer, remains unclear. Thus, we aimed to reveal the role of hepatic FTO in metabolism and in the initiation and progression of HCC in vivo.

Methods: We generated mice with hepatic FTO deficiency (FTO\textsuperscript{−/−}KO). The effect of hepatic FTO on metabolism was investigated by extensive metabolic phenotyping. To determine the impact of hepatic FTO on HCC development, FTO\textsuperscript{−/−}KO and Ctrl mice were subjected to long-term diethylnitrosamine (DEN)-induced HCC-development and the tumor initiation phase was examined via a short-term DEN protocol.

Results: In long-term DEN experiments, FTO\textsuperscript{−/−}KO mice exhibit increased HCC burden compared to Ctrl mice. In the tumor initiation phase, Ctrl mice display a dynamic regulation of FTO upon induction of liver damage, while this response is abrogated in FTO-deficient mice. Proteomic analyses revealed that liver damage-induced increases in FTO expression reduce CUL4A protein abundance. Functionally, simultaneous knockdown of CUL4A reverses the increased hepatocyte proliferation observed upon loss of FTO.

Conclusion: Collectively, our study demonstrates that hepatic FTO is dispensable for the control of energy homeostasis and glucose metabolism. However, we show a protective function of FTO in liver carcinogenesis and suggest the FTO-dependent dynamic mRNA demethylation of CUL4A in the initiation of HCC development contributes to this effect.

Keywords Hepatocellular carcinoma; FTO; Cul4a; m\textsuperscript{6}A

1. INTRODUCTION

Obesity represents an increasing health burden in western societies. The worldwide prevalence more than doubled since 1980 and is continuously increasing [1]. Overweight and obesity are not only major drivers for the development of numerous diseases, such as type 2 diabetes mellitus and cardiovascular diseases but also predispose patients to different forms of cancer [2--5]. Notably, the relative risk of dying from cancer is increased upon obesity, and among all cancer types, liver cancer displays the highest mortality risk of males with increased body mass index (BMI) in the U.S. [4,6]. Hepatocellular carcinoma (HCC) is a malignant transformation of hepatocytes and one of the most frequent causes of cancer death worldwide [7,8]. In light of the growing numbers of obese individuals, HCC incidences are expected to further increase, and thereby novel therapeutic approaches are urgently needed to combat this fatal disease.

Single-nucleotide polymorphisms (SNP) in the fat mass and obesity-associated (FTO) gene have been shown to predispose to obesity in humans [9--14]. FTO-deficient mice display decreased bodyweight and adipose tissue, due to an increase in energy expenditure [13], whereas overexpression of FTO increases food intake and causes obesity in mice [14]. In light of these findings, FTO seems to be a promising target for therapeutic approaches to treat obesity and its...
associated diseases. However, more recently, SNPs within the FTO gene have been found to impinge on other, more distal genes rather than affecting FTO expression itself [15–18]. In detail, regions within the FTO gene have been found to interact with regulatory elements of the RX3 gene, and 1r3x inactivation protects mice against diet-induced weight gain [15]. Furthermore, the RPPGRPTL gene, located close to the transcriptional start site of FTO, is also affected by these SNPs and hypomorphic 1rgrpi1 mice are hyperphagic and obese [16–18]. Therefore, obesity-associated SNPs may affect expression of other genes to dysregulate metabolism in obesity. However, given the severe metabolic alterations observed in mouse models of FTO deficiency and overexpression, which do not influence the intrinsic regions of obesity-associated SNPs, FTO itself is likely to also play a role in the regulation of metabolism.

FTO belongs to the superfamily of alpha-ketoglutarate-dependent hydroxylases and was the first identified demethylase that catalyzes not only demethylation of thymidine and uracil bases in DNA, but also of N6,2′-O-dimethyladenosine (m6Am) and N6-Methyladenosine (m6A) modifications in snRNAs and mRNAs [19–22]. m6Am at +1 A adjacent to the m6CG cap of snRNAs is the preferred target of FTO [23]. Nevertheless, m6Am and m6A are both demethylated by FTO, although m6A to a 100-fold lower extent than m6Am [24].

The highly abundant m6A mRNA modifications are dynamically regulated through a machinery of m6A writers, readers, and erasers [22,25–27]. The m6A methyltransferase complex — referred to as m6A writer — is composed of methyltransferase-like 3 and 14 (METTL3 and METTL14), and their cofactors Wilms tumor-1-associated protein (WTAP), VIRMA (KIAA1429), and RBM15. m6A modifications are directly recognized by so-called readers, which are members of the YT521-B homology (YTH)-domain family. Depending on the reader, an m6A modification can either result in the promotion of mRNA translation or induction of mRNA decay [28–30]. Additionally, m6A readers can impact splicing, nuclear export, and stability of mRNAs [31,32]. m6A modifications can be removed by so-called erasers or m6A demethylases, such as FTO and ALKBH5 [21,33,34].

The best characterized demethylase is FTO, which is highly expressed in the brain, where it critically regulates dopaminergic neurocircuits and locomotor activity [35–37]. However, FTO expression is not only restricted to the brain, but it is also found in many peripheral tissues, including the liver [38,39]. Collectively, the complex dynamic regulation of m6A/m6Am mRNA modifications controls mRNA transcription and translation, and dysregulation of this machinery is highly associated with several diseases, including different types of cancers [40]. In particular, initiation and/or progression of glioblastoma (GBM), acute myeloid leukemia (AML), breast cancer, pancreatic cancer, prostate cancer, cervical cancer, endometrial cancer, and HCC are affected by abnormal m6A modifications or even by dysregulation of key players of the m6A machinery [41–59]. In addition to the dysregulation of m6A writers and readers, both m6A erasers — FTO and ALKBH5 — have been linked to GBM, breast cancer, AML, cervical cancer, and HCC [40,41,43,60–65].

Knockdown of FTO in human HepG2 cells in mouse xenografts reduces tumor volume, suggesting that FTO may exert an oncogenic function in liver cancer via demethylation of pyruvate kinase M2 (PKM2) mRNA [66]. Conversely, increased m6A modifications and reduced FTO levels in human HCC samples compared to matched, non-tumor tissue have been reported [57,58]. Thus, the hepatocyte-specific function of FTO in HCC development remains elusive.

Here, we aimed to ascertain the role of FTO demethylation in DEN-induced HCC using mice with hepatic FTO deficiency. Liver-specific FTO inactivation increased DEN-induced HCC burden, potentially as a consequence of accelerated proliferation. Our findings demonstrate for the first time that hepatic FTO is dynamically regulated upon liver damage and has a protective role in HCC development in vivo.

2. MATERIAL AND METHODS

2.1. Animal care

Male mice (Mus musculus, genetic background C57Bl/6N) were housed in groups of 2–5 mice at 22–24 °C in a specific-pathogen-free animal facility and were exposed to a 12-h light/12-h dark cycle. The access to water and food was unlimited. Either control diet (Sniff, EF D12450B° mod. LS) or normal chow diet (Sniff, R/M-H low phytoestrogen) were fed. The experiments were authorized by the local government authorities and were in accordance with National Institutes of Health (NIH) guidelines.

2.2. Generation of FTO1−/− mice

The FTO1/mouse strain, in which loxp sites flank the exon 3 of the FTO gene, was obtained by EUCOMM and has been described previously [36]. Hepatocyte-specific FTO1−/− mice have been generated by crossing the floxed loxp-flanked FTO allele to Alfp-CreERT2. FTO1/0 and FTO−/− mice were on a C57/BL6N background.

2.3. Glucose tolerance test

To analyze the reaction of mice to hyperglycemic stimuli, a glucose tolerance test was performed. Prior to the experiment, the mice were fasted. Fasted blood glucose was determined by punctuating the tail vain and using a Contour-Next® blood glucose meter and Contour-Next® test stripes. Next, mice were intraperitoneally (i.p.) injected with glucose (2 mg/g bodyweight (BW), Bela-Pharm, Vechta, Germany), and blood glucose levels were measured at 15, 30, 60, and 120 min after injection.

2.4. Insulin tolerance test

Insulin sensitivity was determined by performing an insulin tolerance test. Prior to the experiment, fed blood glucose levels were determined by punctuating the tail vain and using a Contour-Next® blood glucose meter and Contour-Next® test strips. Afterward, mice were injected i.p. with insulin (0.75 U insulin/g BW, Sanofi, Frankfurt, Germany), and blood glucose was measured at 15, 30, and 60 min after injection.

2.5. Long-term diethylnitrosamine (DEN)-induced HCC

At p15, male mice were injected i.p. with 25 mg/kg BW (2.5 mg/ml H2O) DEN (Sigma—Aldrich, Seelze, Germany). The animals were sacrificed 8 months after DEN treatment, and tumor numbers were counted macroscopically.

2.6. Short-term DEN-induced acute liver damage

8-week-old mice were injected i.p. with 100 mg/kg BW DEN and sacrificed 4, 12, 24, and 48 h post-injection.

2.7. Organ preparation

Mice were sacrificed at the end of the experiment using a CO2 chamber. First, epididymal white adipose tissue (WAT) and liver weights were determined. Heart blood was taken, and the liver, WAT, and skeletal muscle were snap-frozen in liquid nitrogen. The organs were stored at −80 °C until further analysis.
2.8. Nuclear magnetic resonance spectroscopy
Total fat and lean mass were measured using a minispec mq 7.5 (Bruker, Billerica, MA).

2.9. Adeno-associated-virus (AAV) injection
Prior to injection, 6-week-old mice were placed under an infrared lamp to ensure proper access to the tail vain. The mice were fixed in a restrainer, and 100 μl of virus in phosphate-buffered saline (PBS, 2.1 × 10^13 genecopies/ml) was injected into the tail vain. AAVs were obtained from Vector Biologs, Malvern, PA (shAAV-256372).

2.10. Cheek bleeding and serum analysis
Blood samples were collected from the submandibular vein using a lancet. Subsequently, blood was centrifuged for 60 min at 17,000 g at 4 °C, and serum was stored at -20 °C.
To monitor liver damage in the serum, alanine aminotransferase (ALT) levels were determined. Additionally, serum triglyceride and cholesterol levels were analyzed. The serum was analyzed by the central lab of the University Hospital in Cologne.

2.11. Enzyme-linked immunosorbent assay (ELISA)
KI67 ELISA was performed to determine the amount of KI67 in livers of ST-DEN-injected mice. The ELISA was performed as described by the manufacturer (Abbexa, Cambridge, UK, abx154289).
Ataxin-10 ELISA was performed to determine the amount of ataxin-10 in the serum of LT-DEN-injected mice at 6 and 8 months of age. The ELISA was performed according to the manufacturer’s instructions (Uscn Life Science, Wuhan, CA). Mouse serum was diluted 1:10.

2.12. Western blot analysis
Tissue was homogenized with a bead homogenizer (MP Biomedicals, Schwerte, Germany) using standard protocols. Membrones were probed with the following antibodies:
anti-β-ACTIN 1:5,000 (Sigma—Aldrich, Seelze, Germany, #A5441, RRID: AB_476744), anti-CCNE1 1:1,000 (Cell Signaling, Denvers, MA, #20808, RRID: AB_2783554), anti-Cleaved CASPASE3 1:200 (Cell Signaling, Denvers, MA, #9661, RRID: AB_2341188), anti-CUL4A 1:5,000 (Abcam, Cambridge, UK, #ab72548, RRID: AB_1268363), anti-FTO 1:5,000 [13], anti-PCNA 1:500 (Cell Signaling, Denvers, MA, #13110, RRID: AB_2636979). Horseradish peroxidase (HRP)-conjugated secondary antibodies were used: polyclonal goat anti-mouse immunoglobulin G (IgG, whole molecule)-peroxidase (Sigma—Aldrich, Seelze, Germany, #A4416, RRID: AB_258167), polyclonal goat anti-rabbit IgG (whole molecule)-peroxidase (Sigma—Aldrich, Seelze, Germany, #A6154, RRID: AB_258284), polyclonal donkey anti-guinea pig IgG-peroxidase (Jackson Immuno Research, West Grove, PA, #706-035-148, RRID: AB_2340447).
ImageJ software was used for western blot quantification [68].

2.13. Quantitative polymerase chain reaction (PCR)
Frozen tissues or cells were homogenized in QiAzet (Qiagen, Hilden, Germany), and RNA was isolated using the RNeasy mini kit (Qiagen, Hilden, Germany) and treated with DNase (79254, Qiagen, Hilden, Germany). RNA was reversely transcribed with a High-Capacity cDNA Reverse Transcription Kit and amplified using TaqMan Gene Expression Master Mix (both Applied Biosystems, Darmstadt, Germany). Relative expression of mRNAs was determined using standard curves based on cDNA derived from the respective tissues, and samples were adjusted for total RNA content by TATA-binding protein (Tbp) quantitative PCR. Calculations were performed by a comparative cycle threshold (Ct) method: starting copy number of test samples was determined in comparison with the known copy number of the calibrator sample (ddCt). The relative gene copy number was calculated as 2-ddCt. Quantitative PCR was performed on an ABI Quantstudio Detector (Applied Biosystems, Darmstadt, Germany). The following Taqman probes (Applied Biosystems, Darmstadt, Germany) were used for gene expression assays: Cul4a (Mm01220732_m1; Mm00461469_m1; Mm00461464_g1; Mm01220734_g1; Mm00461460_g1; Mm00461475_gH), Dagt1 (Mm00515643_m1), Dagt2 (Mm00499536_m1), Fasn (Mm00662319_m1), Flo (Mm00488755_m1), Pparg (Mm00440945_m1), Scd1 (Mm00772920_m1), Srebp1 (Mm00550338_m1), Srebp2 (Mm01306292_m1), Tbp (Mm00446973_m1). Amplification of pronounced Cul4a methylation region in Exon 20 was performed using CAGAGACTATGGAAACGAGAC and ATCTCTGCTGCGAATATCA primer and ACATGCTAACATGACCATCCGTCGGC probe.

2.14. Quantitative proteomics
Fifty micrograms of isolated proteins were precipitated in ice-cold acetone overnight at -20 °C. Afterward, proteins were centrifuged at 10 min at 15,000 g at 4 °C and washed once in 80% aceton (WVR, Darmstadt, Germany). Subsequently, protein pellets were dried to room temperature (RT) for 5 min and resuspended in 6 M of urea/2 M of thio-urea in 10 mM of HEPES (Applichem, Darmstadt, Germany). To monitor liver damage in the serum, alanine aminotransferase (ALT) levels were determined. Additionally, serum triglyceride and cholesterol levels were analyzed. The serum was analyzed by the central lab of the University Hospital in Cologne.

Prior to digestion, proteins were first reduced using 5 M of TCEP for 1 h at RT and alkylated with 40 mM of CAA for 30 min. Protein digestion was performed by incubating for 3.5 h with Lys-C (1:100) (Wako, Neuss, Germany). Subsequently, the urea concentration was diluted to 2 M using 50 mM of ammonium bicarbonate and digested overnight at RT with trypsin (1:100) (Sigma—Aldrich, Seelze, Germany).
Prior to peptide loading, samples were acidified with 1:20 formic acid. StageTips were washed once with methanol (40 g for 1 min) (Roth, Karlsruhe, Germany), once with buffer B (80% acetonitril, 0.1% formic acid, Sigma—Aldrich, Seelze, Germany), and twice with buffer A (0.1% formic acid, Sigma—Aldrich, Seelze, Germany). Subsequently, peptides were loaded on StageTips and washed ones with Buffer A and twice with Buffer B. Dried StageTips were stored at 4 °C until elution and mass spectrometry analysis was performed [69].

Liquid chromatography tandem mass spectrometry (LC-MS/MS) instrumentation consisted of a nanoLC 1200 (ThermoScientific, Schwerte, Germany) coupled via a nano-electrospray ionization source to a QExactive HF-x mass spectrometer. Peptides were separated using an in-house packed (C18 PoroShell, 2.7 μm, Agilent, Santa Clara, CA) 50-cm column (ID: 75 μm) and a binary buffer system: A: 0.1% formic acid and B: 0.1% formic acid in 80% acetonitril. In total, a gradient of 90 min was used with a linear increase from 4% B to 32% B within 75 min, followed by an increase to 95% B and re-equilibration steps.
MS1 spectra were acquired at a mass resolution of 60,000 using an AGC target of 3e6 and a maximum injection time of 20 ms. The mass spectrometer operated in a Top18 data-dependent mode using an MS/MS mass resolution of 7,500 (at 200 m/z), a maximum injection time of 11 ms (AGC target 1e5). The isolation window was set to 1.3 m/z. A normalized collision energy of 28 was used.
Brief Communication

Acquired MS/MS spectra were correlated against the Uniprot Mus Musculus reference proteome (downloaded Jan. 2019) using MaxQuant [70] and the search engine Andromeda [71]. MaxQuant settings were used as default and match-between runs and the MaxLFQ algorithm were enabled. To identify significantly changed proteins, a two-sided t-test was performed. Visualization and analysis of data were performed in Instant Clue [72].

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE [73] partner repository (identifier PXD018223).

2.15. Methyl-RNA-immunoprecipitation (meRIP)
To isolate mRNA from liver lysates, a magnetic mRNA isolation kit (NEB, Frankfurt am Main, Germany) was used. The isolation was performed as described by the manufacturer. The mRNA concentration was determined using a NanoDrop ND-1000 UV-Vis Spectrophotometer. Two micrograms of mRNA was denaturated at 94 °C for 4 min. Ten milligrams of anti-N6-methyladenosine or control mouse immunoglobulin G (IgG) antibody in 450 µl of CLIP buffer (50 mM of Tris-HCl, pH 7.4, 1 M of NaCl, 0.5% NP40, 150 mM of NaCl, Applichem, Darmstadt, Germany, 0.5% NP40, Sigma—Aldrich, Seeze, Germany) containing 2 µl of RNaseOUT (ThermoScientific, Schwerte, Germany) and 0.9 µl of Ethylenediaminetetraacetic acid EDTA (Applichem, Darmstadt, Germany) were added to the mRNA and incubated on a rotor for 1 h at RT. In the meantime, 1.5 mg of Protein A beads (ThermoScientific, Schwerte, Germany) were washed in CLIP buffer and subsequently resuspended in 100 µl of CLIP buffer. After antibody binding, 100 µl of Protein A beads in CLIP buffer were added to the mRNA, and IP was performed on a rotor overnight at 4 °C. Subsequently, IP was washed 3 times in 500 µl of high-salt CLIP buffer (50 mM of Tris-HCl, pH 7.4, 1 M of NaCl, 0.5% NP40), followed by 3 washes in CLIP buffer. To elute immunoprecipitated RNA, the beads were resuspended in 300 µl of elution buffer (5 mM of Tris-HCl pH 7.5, 1 mM of EDTA, 0.05% SDS, Applichem, Darmstadt, Germany) containing 5 µl of Proteinase K (Roche Diagnostics, Mannheim, Germany) and incubated for 1.5 h at 37 °C while shaking gently. Immunoprecipitated mRNA was purified by phenol/chloroform extraction. To this end, 300 µl of 1:1 phenol/chloroform (Roht, Karlsruhe, Germany) were added to eluted mRNA and vortexed thoroughly. Subsequently, mRNA was centrifuged for 10 min at 17,000 g at 4 °C. mRNA containing upper phase was mixed with 600 µl of 100% ethanol (Applichem, Darmstadt, Germany). After centrifugation, mRNA was washed in 70% ethanol and dried for 10 min at 37 °C. The purified mRNA was resuspended in 20 µl of diethyl pyrocarbonate (DEPC, Applichem, Darmstadt, Germany) water, and concentration was determined using a NanoDrop ND-1000 UV-Vis Spectrophotometer. Subsequently, mRNA was reversely transcribed into cDNA and quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed.

2.16. SELECT assay
The select assay was performed as previously described by Xiao et al. [74]. In brief, polya mRNA or RNA oligos (IDT) were mixed with 40 nM of the respective UP and DOWN primer (listed below) and 5 µM of dTTPs in 17 µl 1x CulSmart buffer (NEB). Annealing was performed at a temperature gradient (1 min at 90 °C, 1 min at 80 °C, 1 min at 70 °C, 1 min at 60 °C, 1 min at 50 °C, and 6 min at 40 °C). Three microfilters of Bst 2.0 (NEB) and SplintR (NEB) enzyme mixture (0.01 U Bst 2.0 DNA polymerase, 0.5 U SplintR ligase, 10 nmol ATP) were added and incubated for 20 min at 40 °C. Subsequently, denaturation was performed at 80 °C for 20 min. qRT-PCR was performed on an ABI Quantstudio Detector (Applied Biosystems, Darmstadt, Germany). The 20 µl reaction contained 2x SYBR Select Mastermix (Applied Biosystems), 200 nM of qPCR primer, 2 µl of SELECT reaction and ddH2O. qRT-PCR was run using the following conditions: 1. 1 min at 95 °C; 2. 10 s at 95 °C, 35 s at 60 °C x 40 cycles; 3. 15 s at 95 °C; 4. 1 min at 60 °C; 5. 15 s at 95 °C (ramping rate 0.05 °C/s); 6. hold 4 °C.

Primers used for SELECT:
Cu4m6A2373up: tagcaggactgtagctttttTGGACTCTTTGTTCG
Cu4m6A2373down: 5P- TCCATATAGCTGTCTCTATACagaggctgtagtc
tgctgcat
Cu4m6A2378up: tagcaggactgtagctttTTGAGTTTGGACGTCTTTTG
Cu4m6A2378down: 5P- CTGGTCTTACATAACTTCCagaggctgtagtc
tgctgcat
Cu4m6A2384up: tagcaggactgtagctttGTGACTGTTTGGACTCTTG
Cu4m6A2384down: 5P- CTTTGTCTGTCCCCATATACTagaggctgtagtc
tgctgcat
Cu4m6A2415up: tagcaggactgtagctttGAGCTAGGTGTAGCTGGCC
Cu4m6A2415down: 5P- CATGCGCACAGTGTTGACagaggctgtagtc
tgctgcat
Cu4m6A2427up: tagcaggactgtagctttCTCAGGGAGACCACAG
Cu4m6A2427down: 5P- CACGCTTGGCCTGATGTCCagaggctgtagtc
tgctgcat
Cu4A2381up: tagcaggactgtagctttGTAGTGGAGTGGCTCTT
Cu4A2381down: 5P- TGTTCTGTTCCATATAGCTCCagaggctgtagtc
tgctgcat
Cu4A2412up: tagcaggactgtagctttGTGACTGTGGGACTCTTG
Cu4A2412down: 5P- GCCACGTAGGTACGACagaggctgtagtc
tgctgcat
Cu4A2391up: tagcaggactgtagctttGACAGTGTTGACTGTGTT
Cu4A2391down: 5P- GAGCTGCTTGTCTCTGTCagaggctgtagtc
tgctgcat
RNA oligos:
m6A2415: AUCAGUAACACCAUGUGGCAUGiN6MerACGACCAUGUG ACUGUCUG
A2415: AUCAGUAACACCAUGUGGCAUGACGACCAUGUGACUGUCUG

2.17. Immunohistochemistry and histological analysis
Liver tissue was embedded in tissue-freezing medium (Jung, Heidelberg, Germany) for frozen block preparation. To detect proliferating cells, Ki67 (#ab 15580, Abcam, Cambridge, UK) staining was performed on cryosections of livers. Ki67-positive cells were imaged using a Zeiss Imager fluorescence microscope. The number of Ki67-positive cells was normalized to the total number of cells (4',6-diamidino-2-phenylindole (DAPI)-positive) using ImageJ [68]. Oil-Red-O (Sigma—Aldrich, Seeze, Germany, 00625-25G) staining was performed to visualize hepatic lipid storage. Cryosections of livers were fixed in formalin and subsequently washed in tap water for 10 min. Next, liver sections were rinsed with 60% isopropanol (Roth, Karlsruhe, Germany) and stained for 15 min with Oil red 0 working solution. After rinsing with 60% isopropanol, hematoxylin and eosin staining was performed to visualize nuclei and cytoplasm, respectively.

2.18. Indirect calorimetry
Energy expenditure was measured using indirect calorimetric measurements in a PhenoMaster System (TSE systems, Bad Homburg, Germany). Animals were allowed to adapt to the single housing in metabolic chambers for a training phase of 5 days. During that time, animals were monitored daily to ensure proper adaptation to the drinking and feeding dispensers. Calorimetric measurement was conducted at 22—24 °C over a period of 48—72 h, assessing oxygen uptake.
consumption (VO₂), carbon dioxide production (VCO₂), locomotor activity by interruption of a light beam (light barrier frame, TSE systems, Bad Homburg, Germany), and water and food intake using automated measuring devices (TSE systems, Bad Homburg, Germany) for individually housed mice. Energy expenditure and the respiratory exchange ratio (VCO₂/VO₂) were calculated indirectly from the obtained parameters.

2.9. Quantification and statistical analysis
Data are presented as means ± min. and max. or means ± SEM. Statistical significance was either calculated using a two-tailed unpaired student’s t-test, ordinary one-way analysis of variance (ANOVA), or ordinary two-way ANOVA. Significance was accepted at the level of p* < 0.05, p** < 0.01, p*** < 0.001, and p**** < 0.0001. The respective statistical test that was used is indicated in each figure legend. ImageJ was used for microscopy and Western blot quantification [68]. Visualization and analysis of proteomics data was done in InstantClue [72]. Bar charts and columns were generated in PRISM. Figures were assembled with Adobe Illustrator.

3. RESULTS

3.1. Hepatic FTO deficiency alters body composition in late stage DEN-induced HCC but fails to impact glucose metabolism

To specifically determine the function of hepatic FTO in HCC development, we generated mice with hepatocyte-specific ablation of FTO. Fto<sup>fl/fl</sup>EUCOMM/Wtsi mice were intercrossed with Alfp-Cre mice [75] to remove the loxP flanked exon 3 of the Fto gene specifically in hepatocytes (Supplementary Figure 1A). FTO<sup>fl/fl</sup>; Alfp-Cre<sup>+</sup> (FTO<sup>L-KO</sup>) mice showed reduced Fto mRNA and FTO protein levels in liver lysates when compared to FTO<sup>fl/fl</sup> (Ctrl) mice (Supplementary Figures 1B and C). Of note, the Fto<sup>fl/fl</sup>EUCOMM/Wtsi allele, neither in the loxP-flanked nor in the Cre-mediated deleted state, affects the SNP region in intron 1 of FTO that has been identified in human GWAS studies associated with increased body mass index.

Whole body FTO deficiency protects against obesity due to increased energy expenditure, while whole body FTO overexpression leads to an increase in body and fat mass, as well as to glucose intolerance upon high-fat diet feeding [13,14]. To date, liver FTO function has not been investigated in a genetic mouse model of hepatocyte-specific FTO depletion. Therefore, we set out to metabolically analyze FTO<sup>L-KO</sup> mice and their littermate Ctrl mice. First, body weight was monitored weekly over a period of 18 weeks. However, FTO<sup>L-KO</sup> mice did not show changes in body weight when compared to Ctrl mice (Supplementary Figure 1D).

Consistently, no difference was detected in fat mass and epididymal white adipose tissue (WAT) weight in 18-week-old Ctrl and FTO<sup>L-KO</sup> mice (Supplementary Figures 1E and F). Moreover, hepatic depletion of FTO did not change total liver weights (Supplementary Figure 1G). Given the mild improvement in insulin sensitivity of FTO whole body knockouts and the reduction of glucose tolerance in FTO overexpressing mice, we assessed insulin sensitivity and glucose tolerance in Ctrl and FTO<sup>L-KO</sup> mice (Supplementary Figures 1H and I) [13,14]. However, no difference was observed in either insulin sensitivity (Supplementary Figure 1H) or glucose tolerance (Supplementary Figure 1I) at 13 weeks of age. Blood glucose levels in fed and fasted states remained unchanged in Ctrl and FTO<sup>L-KO</sup> mice (Supplementary Figure 1J). Furthermore, we investigated food intake, activity, respiratory exchange ratio, and energy expenditure (Supplementary Figure 1K, L, M, and N). We found that hepatic depletion of FTO did not change any of those parameters. Thus, hepatic FTO fails to affect whole body energy metabolism, activity, and food intake. Based on the impact of m<sup>6</sup>A methylation in cancer initiation and progression, we aimed to define the role of hepatic FTO in chemically-induced HCC development. To ensure that HCC development is independent of metabolic changes in DEN-injected mice, we monitored body composition and glucose metabolism as part of the 8-month DEN protocol (Figure 1A). Although bodyweight gain was similar between the groups throughout the experiment, FTO<sup>L-KO</sup> mice showed a significant reduction in body weight after 8 months of age (Figure 1B,C). Fat mass and epididymal WAT weight was reduced in mice with hepatic FTO deficiency upon DEN treatment (Figure 1D,E). However, overall insulin sensitivity and glucose tolerance remained largely unaffected in FTO<sup>L-KO</sup> mice at early (3 months) and late time points (6 months) of DEN-induced liver carcinogenesis (Figure 1F,G). Consistently, no differences in blood glucose levels were observed upon hepatic FTO depletion in fed and fasted states (Figure 1H). Recent studies have shown that FTO overexpression in HepG2 and L02 cells increased lipid accumulation [76,77]. Moreover, NASH patients and NASH animal models displayed increased hepatic FTO expression [76,78]. However, Oil-Red-O staining of livers from DEN-injected FTO<sup>L-KO</sup> and Ctrl mice did not display differences in lipid accumulation between the genotypes (Figure 1I). Hepatic FTO deficiency might have an impact on metabolic pathways, such as cholesterol homeostasis, triglyceride and fatty acid synthesis, and glycolysis/glycogenesis. However, expression of the key cholesterol homeostasis regulatory genes Srebp1 and Srebp2 as well as serum cholesterol levels remained unchanged in FTO<sup>L-KO</sup> mice compared to their littermate Ctrl mice (Supplementary Figure 2A). Additionally, expression of central enzymes of triglyceride synthesis Dgat1 and Dgat2 were unaltered in livers of mice with FTO deficiency (Supplementary Figure 2B). In line, serum triglyceride levels did not differ between the genotypes (Supplementary Figure 2B). Moreover, other lipid metabolism regulatory genes, such as Scd1, Pprev, and Fasn, were similarly expressed in livers of both genotypes (Supplementary Figure 2C). Such enzymes in the liver have also been shown to be dysregulated in cancer-induced cachexia [79]. To prove whether decreased body weight is caused by elevated cachexia in the FTO<sup>L-KO</sup> mice, we investigated serum levels of ATAXIN-10, shown to be a potent marker for cancer cachexia [80], in serum of 6 and 8 months-old Ctrl and FTO<sup>L-KO</sup> mice (Supplementary Figure 2D). However, ATAXIN-10 serum levels were unchanged in both cohorts at 6- and 8-month time points of liver carcinogenesis, indicating that Ctrl and FTO<sup>L-KO</sup> mice suffered similarly if at all from cachexia. Taken together, these results ensure that DEN-induced HCC development in Ctrl and FTO<sup>L-KO</sup> cohorts occurred in the absence of large metabolic alterations allowing for the direct comparison between the genotypes independent of an altered metabolism.

3.2. Hepatic FTO expression counteracts DEN-induced HCC development

To monitor DEN-induced HCC progression indirectly via assessing marker of liver damage, we measured alanine aminotransferase (ALT) activity in the serum of 6- and 8-month-old mice. While after 6 months of age, serum ALT activity was low in Ctrl and FTO<sup>L-KO</sup> mice, indicating no or little HCC-associated liver damage, liver damage tended to increase in both genotypes after 8 months (Supplementary Figure 3A). However, no significant differences were obtained between the two genotypes. At 8 months of age, the mice were sacrificed and analyzed for tumor burden. We found that the liver weight of FTO<sup>L-KO</sup> mice was slightly increased when compared to Ctrl animals (Supplementary Figure 3B). In addition, the amount of Ki67-positive cells was slightly elevated, which points toward increased proliferation in livers of
FTO<sup>−/−</sup> KO mice (Supplementary Figure 3C). In contrast, no changes in PCNA levels of liver lysates were detected in FTO<sup>−/−</sup> KO mice (Supplementary Figure 3D). To examine potential differences in apoptosis among the genotypes, cleaved CASPASE3 levels of liver lysates of 8-month-old mice were determined, but no changes were detected (Supplementary Figure 3D).

However, hepatic FTO deficiency resulted in an increased HCC burden from approximately 8 tumors in Ctrl animals to 15 in the FTO-deficient livers on average (Figure 2A). When we analyzed tumor sizes macroscopically, not only the amount of small sized (<2 mm) tumors was increased significantly in FTO<sup>−/−</sup> KO mice, but also the amount of large sized (>2 mm) tumors was 2.6-fold elevated in livers of FTO-
deficient mice (Supplementary Figure 3E). This indicates that FTO deficiency not only impacts HCC initiation (increased tumor numbers) but also HCC progression (increased numbers of larger tumors). Collectively, our experiments reveal that hepatic FTO function plays a protective role in the development of HCC in vivo.

Given the protective effect of hepatic FTO expression in HCC development and the lack of significant changes in proliferation and cell death at late time points, we hypothesized that alterations in the tumor initiation phase might cause increased tumor numbers in FTO-deficient livers after long-term DEN injection. Thus, we investigated the role of FTO in the tumor initiation phase. Therefore, 8-week-old Ctrl and FTO\textsuperscript{KO} mice were injected with a sublethal dose (100 mg/kg) of short-term DEN (ST-DEN) to induce acute liver damage and sacrificed 4 h, 12 h, 24 h, and 48 h after injection, respectively (Figure 2B). Moreover, we analyzed a non-injected control group, referred to as 0 h.

Body weight loss of the mice was monitored and decreased significantly over time in both Ctrl and FTO\textsuperscript{KO} mice to the same extent (Figure 2C). We found that Fto mRNA as well as FTO protein levels were dynamically regulated in the livers of Ctrl mice (Figure 2D,E). In detail, FTO levels were 5- to 10-fold increased 24 h and 48 h post-DEN-injection, respectively (Figure 2E). Thus, these results suggest an important role for FTO in hepatic regeneration after chemically-induced liver damage as well as in the tumor initiation phase of HCC.

### 3.3. Cul4a mRNA is a downstream target of FTO upon acute liver damage

The protective effects of hepatic FTO expression on HCC initiation might be direct, e.g., via demethylation of RNAs encoding proteins involved in tumorigenesis or indirect e.g., via targets that alter global translation or transcription. To determine candidates of damage-induced liver carcinogenesis in the absence of FTO without dependence on anti m\textsuperscript{3}A/m\textsuperscript{5}Am antibody-mediated pull-down of RNA, we performed mass spectrometry-based proteomics analysis of liver lysates isolated from ST-DEN injected Ctrl and FTO\textsuperscript{KO} mice (representative blot) and respective quantification (n = 4 for each timepoint, two-way ANOVA). FTO/β-ACTIN ratio normalized to 0 h Ctrl expression. \# = unspecific band. p* 0.05, p** 0.01, p*** 0.0002, p**** 0.0001. Data are means with SD.
our attention because the expression remained at high levels in FTO-deficient livers, whereas in Ctrl livers CUL4A was significantly reduced 24 h after ST-DEN injection (Figure 3A,B). This regulation was confirmed via Western blot analysis; however, mRNA levels of Cul4a did not reflect the same regulation as CUL4A protein, i.e., mRNA expression decreased upon liver damage but independent of FTO, which suggests a post-transcriptional rather than a transcriptional regulation of Cul4a (Figure 3C,D). Given that CUL4A protein expression reversely correlated with FTO expression in Ctrl livers, we hypothesized that Cul4a might be a potential downstream target of FTO.

To test this hypothesis, we took advantage of a publicly available RNA sequencing dataset [81]. Zhou et al. performed methyl-RNA immunoprecipitation (meRIP) with subsequent RNA sequencing of livers from Ctrl and FTO overexpressing (FTO-OE) mice. We analyzed m6A modification levels of the Cul4a mRNA in the liver of FTO-OE compared to Ctrl mice and identified that Cul4a mRNA is hypomethylated in the FTO-OE mouse in the region between 118 and 183 bp encoded by exon 1 and the most prominent peak at 2340–2427 bp surrounding the translational STOP codon in exon 20 (Supplementary Figures 3F and G). These data supported the hypothesis that Cul4a mRNA might be a downstream target of FTO. To further validate these results in our FTO<sup>−/−</sup> mice, we conducted meRIP on fragmented mRNA isolated from 24 h ST-DEN injected Ctrl and FTO<sup>−/−</sup> mice and subsequently performed qRT-PCR analysis using probes against exons with potential methylation sites, e.g., exons 1/2 and exon 20 as well as in other regions, such as exons 2/3 and 17/18 of the Cul4a transcript (Figure 3E, Supplementary Figure 3H). However, while qRT-PCR with most probes revealed increased appearance of mRNA derived from FTO-deficient livers, only the fragment of exon 20 was significantly enriched in the livers of FTO<sup>−/−</sup> mice (Figure 3E, Supplementary Figure 3H). Notably, direct examination of Cul4a mRNA levels by qRT-PCR without meRIP in livers of Ctrl and FTO<sup>−/−</sup> mice did not show different mRNA abundances with all probes used (Supplementary Figure 3I). Subsequently, we focused on the region 2359–2427 of the Cul4a transcript of exon 20, which showed the highest methylation differences in the FTO<sup>−/−</sup> vs. Ctrl livers, and that additionally represents the region of qRT-PCR probe exon 20 in the meRIP (Figure 3E). In this region, all adenosines within a potential m6A

Figure 3: Hepatic FTO negatively regulates CUL4A in response to short-term DEN-induced liver damage. (A) Volcano plot of log2 ratio of livers of Ctrl and FTO<sup>−/−</sup> at 0h, 12h, and 24h after ST-DEN injection vs the −log10 p value of a two-sided t-test (blue = significantly changed proteins (abs. log2 fold change >0.58 and p-value < 0.05), red = CUL4A). (B) Log2 LFQ intensities of CUL4A in Ctrl and FTO<sup>−/−</sup> liver lysates at 0 h, 12 h, and 24 h after ST-DEN injection. (C) qPCR analysis of Cul4a expression in whole liver of ST-DEN injected Ctrl and FTO<sup>−/−</sup> mice (n = 5 for each timepoint, two-way ANOVA). (D) Western blot analyses of CUL4A and FTO in whole liver lysates isolated from ST-DEN injected Ctrl and FTO<sup>−/−</sup> mice and respective quantification (n = 4 for each timepoint, two-tailed unpaired multiple t-tests). CUL4A/β-ACTIN ratio normalized to 0 h Ctrl expression. (E) Methyl-RNA immunoprecipitation and IGG ctrl immunoprecipitation and subsequent qRT-PCR analysis of Cul4a mRNA pulldown in mRNA isolated from livers of 24 h ST-DEN injected Ctrl and FTO<sup>−/−</sup> mice (n = 5, two-way ANOVA). p*<0.05. Data are means with SD (B–E) or SEM (H).
consensus sequence [82] were considered as potential FTO target adenosines (red), whereas 3 adenosines without consensus sequence were used as controls (Supplementary Figure 4A green). Subsequently, the single-base elongation- and ligation-based qRT-PCR amplification method (SELECT) [74] was performed, which does not depend on use of an anti m6A/m6Am antibody, to identify potential target sites of FTO in Cul4a mRNA of livers isolated from 24 h ST-DEN treated FTO−/−KO and Ctrl mice. Of note, the SELECT method was suitable for determination of m6A modifications in synthetic RNA oligos and the authors used recombinant FTO to assist their detection model, but the in vivo validation was missing. The SELECT method takes advantage of the fact that m6A-modified RNA hinder the single base elongation of Bst DNA polymerase and nick ligation efficiency of SplintR ligase. Two synthetic DNA oligos fused to PCR adapters (up and down probe) anneal to mRNA but leave a nucleotide gap opposite to an m6A site and were used as controls (Supplementary Figure 4A green). Subsequently, 44 bp synthetic RNAs 2415A and 2415m6A homologous to mRNA were used as controls (Supplementary Figure 4B). SELECT results revealed that only adenosine 2415, which is the A of the STOP codon UGA of Cul4a transcript, showed significantly higher CT cycles in FTO−/−KO livers compared to Ctrl livers, suggesting that this specific site was hypermethylated in the FTO−/−KO livers upon ST-DEN treatment (Supplementary Figure 4C). In contrast, not only control As 2381, 2391, and 2412 remained unchanged across the genotypes, but the remaining potential m6A sites 2373, 2378, 2384, and 2427 did not show a difference in CT values, indicating that those sites are not targeted by FTO demethylase in vivo (Supplementary Figures 4D and E). To estimate how much of Cul4a 2415A is methylated in FTO-deficient livers, upon liver damage, we synthesized 44 bp synthetic RNAs 2415A and 2415m6A homologous from 2392 to 2436 flanking the 2415 region to be used in SELECT assay in serial dilutions ranging from 50 to 0.15625 nM (Supplementary Figures 4F−I). These analyses revealed that RNA 2415m6A came up later in the qRT-PCR cycle than 2415A at all concentrations (in average 2.9 cycles later, Supplementary Figure 4I). FTQ−/−KO RNA appeared 2.7 cycles later than Ctrl RNA when using 2415 oligos in SELECT, which suggests that approximately 95% of 2415A is methylated in FTO-deficient Cul4a mRNA upon acute liver damage. Taken together, these results suggest Cul4a mRNA as a target of increased FTO levels upon 24 h ST-DEN-induced liver damage. Consequently, this might alter Cul4a translation in FTO-deficient livers in 24 h ST-DEN, which we have identified by the proteomics approach. However, our experimental set-up does not provide ultimate proof that Cul4a mRNA is demethylated by FTO; thus, alternative conclusions might be drawn regarding how FTO regulates Cul4A protein abundance upon acute liver damage.

3.4 Knockdown of CUL4A in vivo rescues elevated proliferation upon chemically-induced acute liver damage in FTO−/−KO mice

CUL4A is a member of the CULLIN family, which consists of proteins that are part of E3 ubiquitin ligase complexes [83]. Previous findings have shown that CUL4A regulates processes such as cell cycle progression, DNA replication, genomic stability, hematopoiesis, and spermatogenesis [83]. Increased CUL4A expression has been linked to several cancers, including HCC [84,85]. CUL4A was shown to regulate CDK inhibitors and cyclin E1 in Drosophila, resulting in S phase entry, thereby driving cell cycle progression [86]. Western blot analysis revealed that CYCLIN E1 (CCNE1) remained stable in livers of FTO−/−KO mice upon chemically-induced liver damage (Figure 4A), whereas in Ctrl livers, CCNE1 expression was dynamically regulated after ST-DEN-injection (Figure 4A). The elevated expression levels of CCNE1 in FTO-deficient livers proposed an enhanced G1 to S phase entry and thus elevated proliferation in those livers. Our results suggest that elevated translation of Cul4a in livers of FTO−/−KO mice may result in enhanced cell cycle progression and proliferation, ultimately contributing to an increased development of HCC.

As CUL4A promotes cell cycle progression and proliferation, we hypothesized that reducing CUL4A expression in FTO−/−KO mice can protect these animals from an exaggerated DEN-response. Thus, we knocked down CUL4A in vivo in Ctrl and FTO−/−KO mice (Figure 4B). Tail vein injection of an AAV-expressing shRNA, which targets Cul4a, resulted in significantly reduced Cul4a mRNA and CUL4A protein levels in single- and double-deficient livers, but not in mice injected with an AAV-expressing a scrambled control shRNA (scrambl Ctrl) (Figure 4C,D). Hepatocyte-specific depletion of Fto mRNA and FTO protein was confirmed via qRT-PCR and Western blot analysis (Figure 4C,D). To investigate the proliferation in the livers of these mice at 24 h after ST-DEN injections, a Ki67 ELISA was performed (Figure 4E). Indeed, knockdown of Cul4a resulted in a significant reduction of total Ki67 levels in the liver of double-deficient animals when compared to the FTO−/−KO mice. Of note, Ki67 levels in double-deficient livers were completely restored when compared to Ki67 levels in Cul4a single knockdown animals. Thus, reduction of CUL4A expression was sufficient to rescue the elevated proliferation in the livers of FTO−/−KO mice. Collectively, these results suggest that elevated FTO levels during acute liver damage inhibited Cul4a translation, which consequently resulted in reduced proliferation and thus, in reduced HCC burden in vivo.

4. DISCUSSION

FTO whole body deficiency in mice results in metabolic alterations characterized by a lean phenotype due to increased energy expenditure and growth retardation, whereas the overexpression of FTO manifests an opposing phenotype, which is accompanied by an elevated susceptibility to obesity caused by an increase in food intake [13,14,87,88]. However, the extent to which the FTO gene itself contributes to metabolic alterations in human high-risk SNP carriers remains unclear. These SNPs are located within a region of the first intron of the human FTO gene and are one of the strongest known genetic factors associated with human obesity [10,11]. Previous studies have shown that the intronic region harboring high-risk SNPs affect the regulation and expression of distal genes, such as IRX3 and RPRGIP1L [15–18]. In consistency, disruption of Irx3 in mice results in a reduction of body weight up to 30% [15], whereas hypomorphic Rprgip1 mice display a diminished leptin responsiveness and are hyperphagic and obese [18]. Thus, human predisposition to obesity at-risk carriers within the FTO gene may indicate a rather indirect than a direct role for FTO. However, mouse models of FTO deficiency, which do not affect the intronic region of the at-risk SNPs, as well as over expression display metabolic alterations [13,14]. Conditional deletion of FTO revealed that metabolic effects of FTO are mainly mediated by neuronal FTO expression, since neuronal-specific FTO deletion recapitulates most of the metabolic phenotype observed in FTO whole body-deficient mice, while hypothalamic deletion of FTO only partially resembled the metabolic effects [89,90]. Thus, these mouse studies show that FTO itself as well as distal genes can both impact metabolism. To date, FTO expression has not been investigated in a mouse model with specific hepatic ablation. However, given the importance of the liver in the regulation of glucose and lipid metabolism, hepatic FTO may play a role in the regulation of these processes. Hepatic Fto mRNA levels were increased upon fasting in vivo and in vitro, while glucose injections reduced Fto mRNA levels [90,91]. These studies show correlations between glucose metabolism and hepatic Fto expression; however, the extent to which hepatic FTO regulates metabolism...
remains to be investigated. Therefore, we performed extensive metabolic phenotyping in untreated \textit{FTOL}\textsuperscript{-}\textit{KO} mice. In contrast to the above-mentioned studies, we show that hepatocyte-specific \textit{FTO} depletion fails to affect body weight, fat mass, WAT and liver weight, glucose metabolism, and key parameters of energy metabolism. However, body weight, fat mass, and WAT weight are reduced in long-term DEN-injected \textit{FTOL}\textsuperscript{-}\textit{KO} mice when compared to Ctrl mice. Given the unaltered metabolic phenotype in untreated \textit{FTOL}\textsuperscript{-}\textit{KO} mice, those changes are most likely due to enhanced tumor formation in the \textit{FTOL}\textsuperscript{-}\textit{KO} mice, rather than a direct metabolic regulatory function of \textit{FTO}. Of note, metabolic analysis of untreated mice was performed at earlier time points. Therefore, it would also be interesting to investigate metabolic parameters in untreated mice at later time points. Given the previously demonstrated role of \textit{m}\textsubscript{6}A/\textit{m}\textsubscript{6}Am mRNA modifications on the initiation and progression of various cancers in general and on HCC specifically [40], we set out to investigate the function of hepatic FTO in HCC development. Our findings show that FTO function protects against chemically-induced HCC development, since \textit{FTO}\textsuperscript{-}\textit{KO} mice display significantly increased tumor burden. Moreover, \textit{FTO}-deficient, tumor-bearing livers tend to have increased proliferation. In line with our study, HCC patients frequently display increased levels of \textit{m}\textsubscript{6}A mRNA modifications accompanied with increased methyltransferase METTL3 expression [57]. METTL3-overexpressing HepG2 cells show increased proliferative potential in a xenograft model of tumor development, further supporting our findings of increased proliferation in the livers of \textit{FTOL}\textsuperscript{-}\textit{KO} mice during the tumor initiation phase [57]. Hence, high \textit{m}\textsubscript{6}A mRNA modifications increase proliferation in those settings. In contrast, Ma et al. identified decreased \textit{m}\textsubscript{6}A mRNA modifications in human metastatic HCC, which is presumably due to reduced METTL14 expression in tumor tissue [58]. However, they also found decreased FTO expression levels in these tissues, further supporting a role for FTO in human HCC. To investigate the tumor initiation phase in Ctrl and \textit{FTO}\textsuperscript{-}\textit{KO} mice, ST-DEN injections were performed, and the injected mice were sacrificed at different time points after injection. Surprisingly, we found a dynamic regulation of \textit{Fto} mRNA and FTO protein after ST-DEN injections.
in livers of Ctrl mice, which expectedly was absent in FTOL−/−livers. To identify downstream targets of the elevated hepatic FTO expression at 24 h after ST-DEN injection in the Ctrl livers, we performed quantitative proteomics and screened for peptides, whose expression correlated or reversely correlated with FTO expression. Strikingly, CUL4A was downregulated in Ctrl livers at 24 h post ST-DEN injection, whereas it remained unchanged at all time points in liver lysates from FTOL−/− mice, thereby reversely correlating with FTO expression in Ctrl livers. However, Cula mRNA expression levels remained unchanged between the genotypes upon ST-DEN injection. This indicates that Cula mRNA modulated by FTO in Ctrl livers may affect translation rather than transcription. Indeed, m^6^A/m^6^Am have been associated with enhanced mRNA stability and translation. In detail, the 5' cap structure +1 m^6^Am-initiated mRNAs were shown to be more stable than mRNAs, which begin with other nucleotides, due to resistance to the mRNA-decapping enzyme DCP2 [29]. However, publicly available miCIP data on FTO-deficient liver RNA failed to identify m^6^Am modifications in Cula transcript [82]. m^6^A modifications, which are enriched near the 3' UTR and the STOP codon region, have been shown to be preferably translated via YTHDF1-mediated translation promotion [22,29,92]. To find the specific m^6^Am/m^6^Am site, which may be demethylated by FTO upon chemically induced liver damage, meRIP and subsequent qRT-PCR was performed with different probes, specific for exons throughout the Cula mRNA. However, only exon 20 showed significant enrichment after meRIP in FTO-deficient livers after 24 h ST-DEN injection, suggesting that this exon is hypermethylated. m^6^A modifications enhance mRNA translation, which is supported in the translation of the hypermethylated Cula mRNA in FTO-deficient livers, consequently causing elevated CUL4A protein levels observed in our proteomics screen. However, our experimental set-up does not allow discrimination of whether 2415m^6^A of Cula transcript is indeed demethylated by FTO. Mauer et al. recently described that FTO demethylates m^6^Am on snRNAs, which is supported by the nuclear localization of FTO [23]. snRNAs, which are core components of the spliceosome, can mediate alternative splicing. Thus, differential CUL4A protein levels in FTOL−/− mice upon ST-DEN injection may also be caused by altered patterns of alternative splicing of Cula mRNA, mediated by FTO-dependent m^6^Am demethylation of snRNAs. Further experiments are needed to ultimately determine why and how CUL4A protein is increased in FTO-deficient livers upon liver damage. However, CUL4A expression and function has been previously linked to HCC development and progression. The scaffold protein CUL4A binds the DNA damage binding protein 1 (DDB1) and the ring of cullins (ROC) to assemble an E3 ubiquitin ligase complex. This E3 ubiquitin ligase has important functions, including regulation of the cell cycle, DNA replication, genomic stability, hematopoiesis, and spermatogenesis [83]. CUL4A is not only upregulated in several HCC cell lines, but also in human HCC samples [84]. Additionally, CUL4A expression positively correlates with hepatocytete proliferation, while an inverse correlation was found regarding tumor differentiation grade and patient survival [84,85]. Indeed, we found a dysregulation of CCE/CcycilE1, which activates CDK2 and thus induces G0/G1 to S-phase transition, in FTOL−/− livers when compared to the Ctrl mice [93]. Moreover, CUL4A has been shown to regulate G0/G1 to S-phase transition directly [83]. Hence, these data point to increased cell cycle progression accompanied by enhanced proliferation in FTOL−/− livers upon chemically-induced liver damage. Therefore, we investigated the effect of simultaneous CUL4A knockdown in FTOL−/− mice on proliferation. Indeed, additional knockdown of CUL4A is sufficient to completely restore the elevated Ki67 levels of FTOL−/− during the tumor initiation phase. Collectively, our study reveals a protective role of FTO against chemically-induced HCC development. We demonstrate that FTO plays a major role during the initiation phase of tumor development, where it is dynamically upregulated upon acute liver damage. Moreover, FTO might target Cula mRNA to decrease CUL4A protein levels, thereby presumably blocking cell cycle progression and proliferation. Thus, the FTO-CUL4A axis could represent a promising target for developing novel therapeutic approaches to treat HCC.

**AUTHOR CONTRIBUTIONS**

M.J.M., K.S., H.N., L.K., and L.M. conducted the experiments; M.J.M., R.T.U., J.C.B., and F.T.W. designed the experiments, M.J.M., J.C.B., and F.T.W. wrote the paper. J.Z. and S.-B.Q. assisted meRIP-seq analysis.

**ACKNOWLEDGMENTS**

The authors thank Jens Alber, Catherina Baitezel, Anke Lietzau, Patrick Jankowski, and Heike Krämer for excellent technical assistance and Pia Scholl, Nadine Sperrath, and Christiane Schäfer for histological stainings. This work was supported by grants from the German Cancer Aid and CECAD to F.T.W. as well as from the Cologne Graduate School for Ageing Research to M.J.M.

**CONFLICT OF INTEREST**

The authors declare no competing interests.

**APPENDIX A. SUPPLEMENTARY DATA**

Supplementary data to this article can be found online at https://doi.org/10.1016/j.molmet.2020.101085.

**REFERENCES**

[1] WHO, 2016. Obesity and Overweight. who.int.

[2] Ford, E.S., Williamson, D.F., Liu, S., 1997. Weight change and diabetes incidence: findings from a national cohort of US adults. American Journal of Epidemiology 146(3):214–222.

[3] Resnick, H.E., Valsania, P., Halter, J.B., Lin, X., 2000. Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults. Journal of Epidemiology & Community Health 54(8):596–602.

[4] Calle, E.E., Rodriguez, C., Walker-Thurmond, K., Thun, M.J., 2003. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New England Journal of Medicine 348(17):1625–1638.

[5] Meschia, J.F., Bushnell, C., Boden-Alba, B., Braun, L.T., Bravata, D.M., Chaturvedi, S., et al., 2014. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 45(12):3754–3832.

[6] Lew, E.A., Garfinkel, L., 1979. Variations in mortality by weight among 750,000 men and women. Journal of Chronic Diseases 32(8):563–576.

[7] GLOBOCAN, 2018. International agency for Research on cancer (IARC). Available at: https://gco.iarc.fr/2018.

[8] WHO, W.H.O.M.D., 2008.

[9] Scott, J.L., Mohlke, K.L., Bonnycastle, L.L., Willer, C.J., Li, Y., Duren, W.L., et al., 2007. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316(5829):1341–1345.
Brief Communication

[10] Frayling, T.M., Timpson, N.J., Weedon, M.N., Zeggini, E., Freathy, R.M., Lindgren, C.M., et al., 2007. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316(5826):889–894.

[11] Dina, C., Meyre, D., Gallina, S., Durand, E., Korner, A., Jacobson, P., et al., 2007. Variation in FTO contributes to childhood obesity and severe adult obesity. Nature Genetics 39(6):724–726.

[12] Thorleifsson, G., Walters, G.B., Gudbjartsson, D.F., Steinthorsdottir, V., Sulem, P., Helgadottir, A., et al., 2009. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nature Genetics 41(1):18–24.

[13] Fischer, J., Koch, L., Emmerling, C., Vierkotten, J., Peters, T., Bruning, J.C., et al., 2009. Inactivation of the Flo gene protects from obesity. Nature 458(7240):894–896.

[14] Church, C., Moir, L., McMurray, F., Girard, C., Banks, G.T., Teboul, L., et al., 2010. Overexpression of Flo leads to increased food intake and results in obesity. Nature Genetics 42(2):1086–1092.

[15] Smero, S., Tena, J.J., Kim, K.H., Gamaon, E.R., Sakabe, N.J., Gomez-Marin, C., et al., 2014. Obesity-associated variants within FTO form long-range functional connections with IRX3. Nature 507(7492):371–375.

[16] Stratigopoulos, G., Padilla, S.L., LeDuc, C.A., Watson, E., Hattersley, A.T., McCarthy, M.I., et al., 2008. Regulation of Flo/Fitm gene expression in mice and humans. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 294(4):R1185–R1196.

[17] Stratigopoulos, G., LeDuc, C.A., Cremina, M.L., Chung, W.K., Leibl, R.L., 2011. Cut-like homeobox 1 (CUX1) regulates expression of the fat mass and obesity-associated and retnitins pigmentsa GT2Pase regulator-interacting protein-1-like (RGRIP1L) genes and coordinates leptin receptor signaling. Journal of Biological Chemistry 286(3):2155–2170.

[18] Stratigopoulos, G., Martin Carli, J.F., O’Day, D.R., Wang, L., Leduc, C.A., Lanzano, P., et al., 2014. Hxromorphism for RGRIP1L, a ciliary gene vicinal to the FTO locus, causes increased adiposity in mice. Cell Metabolism 19(5):767–779.

[19] Gerken, T., Girard, C.A., Tung, Y.C., Webbey, C.J., Saudek, V., Hewitson, K.S., et al., 2007. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science 318(5855):1469–1472.

[20] Han, Z., Niu, T., Chang, J., Lei, X., Zhao, M., Wang, Q., et al., 2010. Crystal structure of the FTO protein reveals basis for its substrate specificity. Nature 464(7292):1205–1209.

[21] Jia, G., Fu, Y., Zhao, X., Dai, Q., Zheng, G., Yang, Y., et al., 2011. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nature Chemical Biology 15(4):340–347.

[22] Meyer, K.D., Saleter, Y., Zumbo, P., Elemento, O., Mason, C.E., Jaffrey, S.R., 2012. Comprehensive analysis of mRNA methylation reveals enrichment in 3’ UTRs and near stop codons. Cell 149(7):1635–1646.

[23] Mauer, J., Sindelar, M., Despic, V., Guez, T., Hawley, B.R., Vasseur, J.J., et al., 2017. FTO controls reversible m(6)A RNA methylation during snRNA biogenesis. Nature Chemical Biology 13(10):855–867.

[24] Mauer, J., Sindelar, M., Despic, V., Guez, T., Hawley, B.R., Vasseur, J.J., et al., 2019. FTO controls reversible m(6)Am RNA methylation during snRNA biogenesis. Nature Chemical Biology 15(4):340–347.

[25] Mauer, J., Xiao, W., Adhikari, S., Dahal, U., Chen, Y.S., Hao, Y.J., Sun, B.F., et al., 2016. Multiple evidence strands suggest that there may be as few as 19,000 human protein-coding genes. Human Molecular Genetics 23(22):5866–5878.

[26] The human protein atlas, 2019. Available from: https://www.proteinatlas.org/.

[27] Wang, X., Lu, Z., Gomez, A., Hon, G.C., Yue, Y., Han, D., et al., 2014. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature 505(7481):117–120.

[28] Wang, X., Zhao, B.S., Roundtree, I.A., Lu, Z., Han, D., Ma, H., et al., 2015. N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell 161(6):1388–1399.

[29] Shi, H., Wang, X., Lu, Z., Zhao, B.S., Ma, H., Hsu, P.J., et al., 2017. YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Research 27(3):315–328.

[30] Xiao, W., Adhikari, S., Dahal, U., Chen, Y.S., Hao, Y.J., Sun, B.F., et al., 2016. Nuclear m(6)A reader YTHDC1 regulates mRNA splicing. Molecular Cell 61(4):507–519.

[31] Sun, T., Wu, R., Ming, L., 2019. The role of m6A RNA methylation in cancer. Biomedicine & Pharmacotherapy 112:108613.
Zhang, C., Zhi, W.I., Lu, H., Samanta, D., Chen, I., Gabrielson, E., et al., 2016. MOLECULAR METABOLISM 42 (2020) 101085

Zhang, C., Samanta, D., Lu, H., Bullen, J.W., Zhang, H., Chen, I., et al., 2016.

Kwok, C.T., Marshall, A.D., Rasko, J.E., Wong, J.J., 2017. Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia. Journal of Hematology & Oncology 10(1):39.

He, Y., Hu, H., Wang, Y., Yuan, H., Lu, Z., Wu, P., et al., 2016. ALKBH5 inhibits pancreatic cancer cell motility by decreasing long non-coding RNA KCNK15-AS1 methylation. Cellular Physiology and Biochemistry 48(2):838–846.

Chen, J., Sun, Y., Xu, X., Wang, D., He, J., Zhou, H., et al., 2017. YTH domain family 2 orchestrates epithelial-mesenchymal transition/proliferation dichotomy in pancreatic cancer cells. Cell Cycle 16(23):2259–2271.

Li, J., Meng, S., Xu, M., Wang, S., He, L., Xu, X., et al., 2018. Downregulation of N(6)-methyladenosine binding YTHDF2 protein mediated by miR-493-3p suppresses prostate cancer by elevating N(6)-methyladenosine levels. Oncotarget 7(4):64527–64542.

Zhou, S., Bai, Z.L., Xia, D., Zhao, Z.J., Zhao, R., Wang, Y.Y., et al., 2018. FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting beta-catenin through mRNA demethylation. Molecular Carcinogenesis 57(5):590–597.

Chen, M., Wei, L., Law, C.T., Tsang, F.H., Shen, J., Cheng, C.L., et al., 2018. RNA N6-methyladenosine demethylation. Science 362(6412):529–543.

Yang, Z., Li, J., Feng, G., Gao, S., Wang, Y., Zhang, S., et al., 2017. MicroRNA-145 modulates N(6)-methyladenosine levels by targeting the 3'-untranslated mRNA region of the N(6)-methyladenosine binding YTH domain family 2 protein. Journal of Biological Chemistry 292(9):3614–3623.

Bokar, J.A., Stambough, M.E., Polayes, D., Matera, A.G., Rotman, F.M., 1997. Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase. RNA 3(11):1233–1247.

Liu, J., Yan, H., Han, D., Wang, X., Fu, Y., Zhang, L., et al., 2014. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nature Chemical Biology 10(2):93–95.

Schwartz, S., Mumbach, M.R., Jovanovic, M., Wang, T., Maciag, K., Bushkin, G.G., et al., 2014. Perturbation of mi6A writers reveals two distinct classes of mRNA methylation at internal and 5' sites. Cell Reports 8(1):284–296.

Fang, H., Chen, C.K., Pickering, B.F., Chow, A., Jackson, C., Guttman, M., et al., 2016. m6A RNA methylation promotes XIST-mediated transcriptional repression. Nature 537(7620):369–373.

Li, J., Zhu, L., Shi, Y., Liu, J., Lin, L., Chen, X., 2019. m6A demethylase FTO promotes hepatocellular carcinoma tumorigenesis via mediating PKM2 demethylation. American Journal of Translational Research 11(9):6084–6092.

Dubiel, D., Sintig, W., Kehne, T., Dubiel, W., Naumann, M., 2017. CuO-induced myelodysplasia is crucial for gradual lipid droplet formation during adipogenesis. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1864(8):1405–1412.

Schneider, C.A., Rasband, W.S., Eliceiri, K.W., 2012. NIH Image to ImageJ: 25 years of image analysis. Nature Methods 9(7):671–675.

Rappsilber, J., Ishihama, Y., Mann, M., 2003. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Analytical Chemistry 75(3):663–670.

Cox, J., Mann, M., 2008. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nature Biotechnology 26(12):1367–1372.

Kellendonk, C., Opferk, C., Anlag, K., Schütz, G., Aisen, J., Mann, M., 2011. Andromeda: a peptide search engine integrated into the MaxQuant environment. Journal of Proteome Research 10(4):1794–1805.

Nolte, H., MacVicar, T.D., Tellkamp, F., Kruger, M., 2018. Instant Clue: a software suite for interactive data visualization and analysis. Scientific Reports 8(1):12648.

Perez-Riverol, Y., Cossardas, A., Bai, J., Bernal-Llinares, M., Hewapathirana, S., Kundu, D.J., et al., 2019. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Research 47(1):D442–D450.

Xiao, Y., Wang, Y., Tang, Q., Wei, L., Zhang, X., Jia, G., 2018. An elongation- and ligation-based qPCR amplification method for the radiolabeling-free detection of locus-specific N(6)-methyladenosine modification. Angewandte Chemie International Edition in English 57(49):15995–16000.

Guo, J., Ren, W., Li, A., Ding, Y., Guo, W., Su, D., et al., 2013. Fat mass and obesity-associated gene enhances oxidative stress and lipogenesis in nonalcoholic fatty liver disease. Digestive Diseases and Sciences 58(4):1004–1009.

Kang, H., Zhang, Z., Yu, L., Li, Y., Liang, M., Zhou, L., 2018. FTO reduces mitochondria and promotes hepatic fat accumulation through RNA demethylation. Journal of Cellular Biochemistry 119(7):5676–5685.

Lim, A., Zhou, J., Sinha, R.A., Singh, B.K., Ghosh, S., Lim, K.H., et al., 2016. Hepatic FTO expression is increased in NASH and its silencing attenuates palmitic acid-induced lipotoxicity. Biochemical and Biophysical Research Communications 479(3):476–481.

Jones, A., Friedrich, K., Rohm, M., Schafer, M., Algire, C., Kulozik, P., et al., 2013. TSC22D4 is a molecular output of hepatic wounding metabolism. EMBO Molecular Medicine 5(2):294–308.

Schaf, M., Oeing, C.U., Rohm, M., Baytas-Temel, E., Lehnmann, L.H., Bauer, R., et al., 2016. Ataxin-10 is part of a cachexokine cocktail triggering cardiac metabolic dysfunction in cancer cachexia. Molecular Metabolism 5(5):67–78.

Zhou, J., Wan, J., Shu, X.E., Mao, Y., Liu, X.M., Yuan, X., et al., 2018. N(6)-Methyladenosine guides mRNA alternative translation during integrated stress response. Molecular Cell 69(4):636–647 e7.

Linder, B., Grohlik, A.V., Olieren-George, A.O., Meydan, C., Mason, C.E., Jaffrey, S.R., 2015. Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nature Methods 12(8):767–772.

Sharma, P., Nag, A., 2014. COL4A ubiquitin ligase: a promising drug target for cancer and other human diseases. Open Biology 4:130217.
[84] Yasui, K., Arii, S., Zhao, C., Imoto, I., Ueda, M., Nagai, H., et al., 2002. TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology 35(6):1476–1484.

[85] Pan, Y., Wang, B., Yang, X., Bai, F., Xu, Q., Li, X., et al., 2015. CUL4A facilitates hepatocarcinogenesis by promoting cell cycle progression and epithelial-mesenchymal transition. Scientific Reports 5:17006.

[86] Higa, L.A., Yang, X., Zheng, J., Banks, D., Wu, M., Ghosh, P., et al., 2006. Involvement of CUL4 ubiquitin E3 ligases in regulating CDK inhibitors Dacapo/p27Kip1 and cyclin E degradation. Cell Cycle 5(1):71–77.

[87] Boissel, S., Reish, O., Proulx, K., Kawagoe-Takaki, H., Sedgwick, B., Yeo, G.S., et al., 2009. Loss-of-function mutation in the dioxygenase-encoding FTO gene causes severe growth retardation and multiple malformations. The American Journal of Human Genetics 85(1):106–111.

[88] McMurray, F., Church, C.D., Larder, R., Nicholson, G., Wells, S., Teboul, L., et al., 2013. Adult onset global loss of the fto gene alters body composition and metabolism in the mouse. PLoS Genetics 9(1):e1003166.

[89] Gao, X., Shin, Y.H., Li, M., Wang, F., Tong, Q., Zhang, P., 2010. The fat mass and obesity associated gene FTO functions in the brain to regulate postnatal growth in mice. PLoS One 5(11):e14005.

[90] Poritsanos, N.J., Lew, P.S., Mizuno, T.M., 2010. Relationship between blood glucose levels and hepatic Fto mRNA expression in mice. Biochemical and Biophysical Research Communications 400(4):713–717.

[91] Mizuno, T.M., Lew, P.S., Luo, Y., Leckstrom, A., 2017. Negative regulation of hepatic fat mass and obesity associated (Fto) gene expression by insulin. Life Sciences 170:50–55.

[92] Liu, J., Li, K., Cai, J., Zhang, M., Zhang, X., Xiong, X., et al., 2020. Landscape and regulation of m(6)A and m(6)Am methylome across human and mouse tissues. Molecular Cell 77(2):426–440 e6.

[93] Clurman, B.E., Sheaff, R.J., Thress, K., Groudine, M., Roberts, J.M., 1996. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes & Development 10(16):1979–1990.